Mental Health

Xanax is indicated for the acute treatment of generalized anxiety disorder and treatment of panic disorder with or without agoraphobia in adults.

David Olson, PhD, the chief innovation officer, head of scientific advisory board, and co-founder of delix therapeutics and an associate professor at University of California, Davis, discusses psychedelics and other psychoplastogens in the treatment of brain and mental health disorders.

Vraylar is an atypical antipsychotic indicated for the treatment of adult patients with schizophrenia and for manic, mixed, or depressive episodes for patients with bipolar I disorder.

Prevalence of type 2 diabetes has been found higher in people with bipolar disorder, schizophrenia, and major depression compared to the general population.

Universal school-based depression screening shows promise addressing mental health conditions in students.

Mean changes from baseline in weight, fasting glucose, total cholesterol, triglycerides, and low-density lipoprotein cholesterol were similar between lumateperone and placebo.

A panel of experts discuss the future of psychedelic medicine and the role of the pharmacy in that future.

Researchers to explore possible approaches for designing small molecule therapeutics to combat depression.

Study results show that those who completed CBT-AD sessions were more than 2.5 times more likely to achieve undetectable viral loads than those who underwent the usual care.

Individuals taking selective serotonin reuptake inhibitors, particularly fluoxetine (Prozac), were less likely to die of the virus than those in a matched control group, study results show.

The odds of visiting an ED for anxiety were 2.8 times greater than for non-depressed individuals.

Ismail Lourido Ali, the director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses continuing education opportunities for pharmacists to get trained on the proper use and administration of psychedelic drugs.

Ron Aung-Din, MD, the clinical medical advisor of Pyscheceutical, and Chad Harman, the CEO of Pyscheceutical, discuss a novel approach for administering psychedelics for the treatment of brain disorders that does not induce hallucinogenic effects.

About 29% of the risk for obsessive-compulsive disorder is attributable to differences in single nucleotide polymorphisms between individuals and the control group, study results show.

Reports of depression, anxiety and stress have surged since the beginning of the COVID-19 pandemic in 2020.

Jessica Louie, host of The Burnout Doctor Podcast, discussed burnout among pharmacy students and how to have a long-term perspective on mental health.

Ketamine Wellness Centers also offers a Hero Discount at clinics to cover partial out-of-pocket costs for military veterans and first responders not covered by the VA-CCN partnerships.

Those with attention-deficit/hyperactivity disorder are much more likely to have GAD at some point in their lives than others who do not have it.

Burnout among pharmacy team members can be minimized through workflow adjustment strategies and cultivating a positive workplace culture.

Practicing mindfulness was associated with fewer psychological symptoms, such as posttraumatic stress, depression, and anxiety.

Ten quiz questions to assess your knowledge on common symptoms and treatments for bipolar disorders.

The trial randomized patients to receive TV-46000 once monthly, TV-46000 once every 2 months, or placebo, and found that patients had improved outcomes on TV-46000 regardless of dosing schedule.

The phase 3 clinical trials evaluated the efficacy and safety of cariprazine as an adjunctive treatment for these patients.

Study addresses the impact of COVID-19 on the mental health of older people.

Kyle Detwiler, CEO of Clever Leaves, discusses his company’s donation of $1 million in medical-grade cannabis to research organizations for the purposes of advancing medical research.